NPM1 and acute myeloid leukemia: This therapeutic potential was translated to amouse model of AML with NPM1 C+ mutation, as intraperitoneal administrationof UCM-13369 resulted in a reduction of tumor infiltration comparedto the untreated group, although no increase in mice survival wasobserved (Figure 6B,C).